Peng Jing, Yuan Yi-Ming, Zhang Zhi-Chao, Hong Quan, Cui Wan-Shou, Gao Bing, Song Wei-Dong, Xin Zhong-Cheng
Center of Andrology, The First Hospital of Peking University, Beijing 100009, China.
Zhonghua Nan Ke Xue. 2013 May;19(5):443-5.
To evaluate the effect of daily low-dose tadalafil on erectile dysfunction (ED) induced by pelvic fracture urethral disruption (PFUD).
This study included 46 cases of PFUD-induced ED treated from Jan 2008 to Dec 2011. The patients were aged 33.9 +/- 7.2 years (range 25 -51 yr), and the interval between injury and treatment was 19.6 +/- 12.7 months (range 3 - 72 mo), all with normal erectile function before PFUD. Based on the nocturnal penile tumescence and rigidity (NPTR) recorded by erectometry without medication of phosphodiesterase type 5 inhibitor (PDE-5I), the patients were divided into an abnormal nocturnal erection group and a non-nocturnal erection group, and treated with tadalafil 10 mg once daily for 3 months. The therapeutic effect was evaluated by IIEF-5 scores and the rate of yes responses to questions 2 and 3 of the Sexual Encounter Profile (SEP).
Totally 38 (82.6%) of the patients accomplished the treatment and follow-up, 26 (68.4%) in the abnormal nocturnal erection group and 12 (31.6%) in the non-nocturnal erection group. After 3 months of daily tadalafil treatment at 10 mg, the IIEF-5 scores were significantly improved in the abnormal nocturnal erection group than in the non-nocturnal erection group (P < 0.05), and the rate of yes responses to SEP2 and SEP3 was remarkably higher in the former than in the latter (76.9% vs 41.7% and 65.4% vs 25.0%, P < 0.05).
Daily low-dose tadalafil can effectively improve the erectile function of PFUD-induced ED patients, particularly in those with nocturnal erection.
评估每日低剂量他达拉非对骨盆骨折尿道断裂（PFUD）所致勃起功能障碍（ED）的疗效。
本研究纳入了2008年1月至2011年12月期间治疗的46例PFUD所致ED患者。患者年龄为33.9±7.2岁（范围25 - 51岁），受伤至治疗的间隔时间为19.6±12.7个月（范围3 - 72个月），所有患者在PFUD前勃起功能均正常。根据未使用5型磷酸二酯酶抑制剂（PDE - 5I）时通过硬度测量记录的夜间阴茎肿胀和硬度（NPTR），将患者分为夜间勃起异常组和非夜间勃起组，并给予他达拉非10毫克每日一次，治疗3个月。通过国际勃起功能指数-5（IIEF - 5）评分以及性活动记录表单（SEP）中问题2和问题3的肯定回答率评估治疗效果。
共有38例（82.6%）患者完成治疗及随访，其中夜间勃起异常组26例（68.4%），非夜间勃起组12例（31.6%）。每日10毫克他达拉非治疗3个月后，夜间勃起异常组的IIEF - 5评分较非夜间勃起组显著改善（P < 0.05），且前者对SEP2和SEP3的肯定回答率明显高于后者（76.9%对41.7%以及65.4%对25.0%，P < 0.05）。
每日低剂量他达拉非可有效改善PFUD所致ED患者的勃起功能，尤其是对有夜间勃起的患者。
